TriSalus Life Sciences Inc. (TLSI) - Total Liabilities
Based on the latest financial reports, TriSalus Life Sciences Inc. (TLSI) has total liabilities worth $55.90 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check TLSI financial resilience to evaluate the company's liquid asset resilience ratio.
TriSalus Life Sciences Inc. - Total Liabilities Trend (2021–2025)
This chart illustrates how TriSalus Life Sciences Inc.'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see TLSI asset base.
TriSalus Life Sciences Inc. Competitors by Total Liabilities
The table below lists competitors of TriSalus Life Sciences Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Asia Aviation Public Company Limited
F:55AA
|
Germany | €61.59 Billion |
|
Eyepoint Pharmaceuticals Inc
NASDAQ:EYPT
|
USA | $51.51 Million |
|
Interarch Building Products Limited
NSE:INTERARCH
|
India | Rs-8.81 Billion |
|
Timberland Bancorp Inc
NASDAQ:TSBK
|
USA | $1.74 Billion |
|
Best Pacific International Holdings Limited
F:NWQ
|
Germany | €2.77 Billion |
|
Oneconnect Financial Technology Co
NYSE:OCFT
|
USA | $1.32 Billion |
|
Chongqing Sifang New Material Co. Ltd.
SHG:605122
|
China | CN¥1.72 Billion |
|
AVCON Information Tech
SHE:300074
|
China | CN¥482.85 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down TriSalus Life Sciences Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of TriSalus Life Sciences Inc. to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.35 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 8.53 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.90 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how TriSalus Life Sciences Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for TriSalus Life Sciences Inc. (2021–2025)
The table below shows the annual total liabilities of TriSalus Life Sciences Inc. from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $69.19 Million | +38.76% |
| 2024-12-31 | $49.87 Million | -3.48% |
| 2023-12-31 | $51.66 Million | +50.54% |
| 2022-12-31 | $34.32 Million | +394.94% |
| 2021-12-31 | $6.93 Million | -- |
About TriSalus Life Sciences Inc.
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial… Read more